Nafamostat Mesylate

Catalog No.S1386

Nafamostat mesilate is a synthetic serine protease inhibitor, used as an anticoagulant during hemodialysis.

Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
USD 310 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Nafamostat Mesylate Chemical Structure

Nafamostat Mesylate Chemical Structure
Molecular Weight: 539.58

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

Nafamostat Mesylate is available in the following compound libraries:

Product Information

  • Compare Serine Protease Inhibitors
    Compare Serine Protease Products

Product Description

Biological Activity

Description Nafamostat mesilate is a synthetic serine protease inhibitor, used as an anticoagulant during hemodialysis.
Targets serine protease [1]
In vitro Nafamostat mesilate significantly inhibits the release of platelet beta-thromboglobulin (beta TG) at 60 and 120 min. Nafamostat mesilate (NM) prevents any significant release of neutrophil elastase; at 120 min, plasma elastase-alpha 1-antitrypsin complex is 0.16 mg/mL in the NM group and 1.24 mg/mL in the control group. Nafamostat mesilate completely inhibits formation of complexes of C1 inhibitor with kallikrein and FXIIa. [1] Nafamostat mesilate inhibits several proteases which may be importantly involved in the pathophysiology of disseminated intravascular coagulation (DIC).Nafamostat mesilate inhibits extrinsic pathway activity (TF-F.VIIa mediated-F.Xa generation) in a concentration dependent manner with IC50 of 0.1 μM. [2] Nafamostat mesilate produces concentration-dependent inhibition of the initial-phase transient component of biphasic ASIC3 currents with an IC50 value of approximately 2.5 mM. [3]
In vivo Nafamostat mesilate (10 mg/kg) inhibits scratching induced by tryptase but not by histamine and serotonin. Nafamostat mesilate (1-10 mg/kg) produces the dose-dependent inhibition of scratching induced by intradermal compound 48/80 (10 mg/site). Nafamostat mesilate (10 mg/kg) suppresses tryptase activity in the mouse skin. [4] Nafamostat mesilate inhibits gemcitabine-induced NF-kappaB activation, enhances apoptosis by gemcitabine and suppresses pancreatic tumor growth. Nafamostat mesilate combined with Gemcitabine improves the body weight loss of mice induced by Gemicitabine. [5]

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesBaboonDogMonkeyRabbitGuinea pigRatHamsterMouse
Weight (kg)121031.
Body Surface Area (m2)
Km factor202012128653
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)


[1] Sundaram S, et al. Thromb Haemost, 1996, 75(1), 76-82.

[2] Uchiba M, et al. Thromb Res, 1994, 74(2), 155-161.

view more

Chemical Information

Download Nafamostat Mesylate SDF
Molecular Weight (MW) 539.58


CAS No. 82956-11-4
Storage 3 years -20℃Powder
6 months-80℃in solvent (DMSO, water, etc.)
Synonyms FUT-175
Solubility (25°C) * In vitro DMSO 20 mg/mL (37.06 mM)
Water 53 mg/mL (98.22 mM)
Ethanol <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 6-carbamimidoylnaphthalen-2-yl 4-guanidinobenzoate dimethanesulfonate

Research Area

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Serine Protease Products

  • Alvelestat (AZD9668)

    Alvelestat (AZD9668) is an oral, highly selective inhibitor of neutrophil elastase (NE) with IC50 and Ki of 12 nM and 9.4 nM, at least 600-fold more selective over other serine proteases. Phase 2.


    AEBSF HCl is a broad spectrum, irreversible serine protease inhibitor.

  • Leupeptin Hemisulfate

    Leupeptin Hemisulfate is a reversible inhibitor of serine and cysteine proteases.

  • PMSF

    PMSF is an irreversible serine/cysteine protease inhibitor.

  • MG-132

    MG-132 is an inhibitor of proteasome with IC50 of 100 nM, and also inhibits calpain with IC50 of 1.2 μM.

  • Bortezomib (PS-341)

    Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • MLN9708

    MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

Recently Viewed Items

Tags: buy Nafamostat Mesylate | Nafamostat Mesylate ic50 | Nafamostat Mesylate price | Nafamostat Mesylate cost | Nafamostat Mesylate solubility dmso | Nafamostat Mesylate purchase | Nafamostat Mesylate manufacturer | Nafamostat Mesylate research buy | Nafamostat Mesylate order | Nafamostat Mesylate mouse | Nafamostat Mesylate chemical structure | Nafamostat Mesylate mw | Nafamostat Mesylate molecular weight | Nafamostat Mesylate datasheet | Nafamostat Mesylate supplier | Nafamostat Mesylate in vitro | Nafamostat Mesylate cell line | Nafamostat Mesylate concentration | Nafamostat Mesylate nmr
Contact Us